All Outputs (8)

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2024)
Journal Article

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases (2024)
Journal Article

Objective To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s). Methods Adu... Read More about Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Working Paper

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Application and Extension of the Alcohol Recovery Narratives Conceptual Framework (2023)
Journal Article

Recovery narratives are personal stories of health problems and recovery. A systematic review proposed a conceptual framework characterising alcohol misuse recovery narratives, consisting of eight principal dimensions, each with types and subtypes. T... Read More about Application and Extension of the Alcohol Recovery Narratives Conceptual Framework.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article

Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study (2007)
Journal Article

There is debate over the mortality and malignancy risk in people with primary biliary cirrhosis (PBC) and whether this risk is reduced by use of ursodeoxycholic acid. To investigate this issue, we identified 930 people with PBC and 9,202 control subj... Read More about Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study.

Fracture Risk in People With Primary Biliary Cirrhosis: A Population-Based Cohort Study (2006)
Journal Article

Background & Aims: Controversy exists as to whether people with primary biliary cirrhosis (PBC) have an increased risk of developing osteoporosis and the extent to which this may translate into an increased risk of fracture. We have performed a coh... Read More about Fracture Risk in People With Primary Biliary Cirrhosis: A Population-Based Cohort Study.